Last reviewed · How we verify

NCT03473496: MM

CAR-T Cells Therapy in Relapsed/Refractory Multiple Myeloma

Terminated NA Last updated 15 March 2024
What this trial tests

NA trial testing CART therapy in Relapsed/Refractory multiple myeloma in Relapsed/Refractory Multiple Myeloma(MM) in 2 participants. Terminated before completion.

Timeline
1 March 2018
Primary endpoint
31 January 2020
31 January 2020

Quick facts

Lead sponsorZhujiang Hospital
PhaseNA
StatusTerminated
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment2
Start date1 March 2018
Primary completion31 January 2020
Estimated completion31 January 2020
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Zhujiang Hospital

Who can join

18 and older, any sex, with Relapsed/Refractory Multiple Myeloma(MM). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Multiple myeloma（MM） is one of the most common malignant diseases in the blood system.There is still no cure for the disease which only control the development of the disease in various ways.Chimeric Antigen Receptor-transduced T cell (CAR-T) therapy is one of revolutionary targeted immunotherapy.The efficacy of CAR-T cells for the treatment of acute B lymphocytic leukemia has been widely recognized, and several clinical trials have been reported in the treatment of multiple myeloma with CAR-T cells.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

  1. CAR T Cell Therapy for Neuroblastoma.
    Richards RM, Sotillo E, Majzner RG. · · 2018 · cited 126× · PMID 30459759 · DOI 10.3389/fimmu.2018.02380
  2. CAR T-cell therapy in multiple myeloma: more room for improvement.
    Teoh PJ, Chng WJ. · · 2021 · cited 123× · PMID 33927192 · DOI 10.1038/s41408-021-00469-5
  3. CAR T therapies in multiple myeloma: unleashing the future.
    Sheykhhasan M, Sheykhhasan M, Ahmadieh-Yazdi A, Vicidomini R, et al · · 2024 · cited 109× · PMID 38438559 · DOI 10.1038/s41417-024-00750-2
  4. Dual Targeting to Overcome Current Challenges in Multiple Myeloma CAR T-Cell Treatment.
    van der Schans JJ, van de Donk NWCJ, Mutis T. · · 2020 · cited 71× · PMID 32850436 · DOI 10.3389/fonc.2020.01362
  5. Chimeric Antigen Receptor-Modified T Cell Therapy in Multiple Myeloma: Beyond B Cell Maturation Antigen.
    Timmers M, Roex G, Wang Y, Campillo-Davo D, et al · · 2019 · cited 67× · PMID 31379824 · DOI 10.3389/fimmu.2019.01613
  6. CAR T-Cells in Multiple Myeloma: State of the Art and Future Directions.
    Rodríguez-Lobato LG, Ganzetti M, Fernández de Larrea C, Hudecek M, et al · · 2020 · cited 66× · PMID 32850376 · DOI 10.3389/fonc.2020.01243
  7. The expansion of targetable biomarkers for CAR T cell therapy.
    Townsend MH, Shrestha G, Robison RA, O'Neill KL. · · 2018 · cited 60× · PMID 30031396 · DOI 10.1186/s13046-018-0817-0
  8. Cancer stem cell-targeted chimeric antigen receptor (CAR)-T cell therapy: Challenges and prospects.
    Masoumi J, Jafarzadeh A, Abdolalizadeh J, Khan H, et al · · 2021 · cited 56× · PMID 34386318 · DOI 10.1016/j.apsb.2020.12.015

Verify or expand the search:

Other recruiting trials for Relapsed/Refractory Multiple Myeloma(MM)

Currently open trials in the same condition.

Other Zhujiang Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03473496.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing